Basic Rifaximin Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In Canada (English): Glumetza, Glucophage
• ATC Code: A10BA02
• Forms & Dosages: Standard tablet 250 mg, 500 mg, 850 mg, 1000 mg; extended‑release tablets 500 mg, 750 mg, 1000 mg; oral solution 500 mg/5 mL
• Manufacturers In Canada (English): Local generics and suppliers such as Apotex and other global generic suppliers are commonly referenced in listings
• Registration Status In Canada (English): Listed brands in Canada include Glumetza and Glucophage; regulatory labelling and monographs should be checked for current registration details
• OTC / Rx Classification: Prescription‑only medicine (Rx) in nearly all countries

Latest Research Highlights

Are you wondering what recent studies say about rifaximin for hepatic encephalopathy, IBS‑D and traveller’s diarrhoea?

Multiple international meta‑analyses published between 2022 and 2025 reinforce rifaximin’s role in reducing recurrence of hepatic encephalopathy when added to lactulose.

Randomised trials support short‑course rifaximin 200 mg three times daily for traveller’s diarrhoea caused by noninvasive E. coli strains.

Clinical trials and pooled analyses show rifaximin 550 mg twice daily added to lactulose consistently reduces HE‑related hospital readmissions in adults.

For IBS‑D, randomised data show rifaximin 550 mg three times daily for two weeks reduces global IBS symptoms and bloating compared with placebo.

Evidence for long‑term remission in IBS‑D is modest, and many patients require repeat courses over months.

Canadian province‑level cohort analyses mirror international outcomes but highlight access disparities and delayed refills in rural and Indigenous communities.

The following table summarises indications, typical doses and a key trial outcome for each listed use.

Canadian Cohort Readmission Reduction %

Shared decision‑making is important because repeat courses and cost must be weighed for each patient before prescribing rifaximin or branded products such as Zaxine 550 mg.

Clinical Effectiveness In Canada

Which coverage and real‑world data inform rifaximin use here in Canada?

Health Canada‑labelled indications and provincial formulary listings shape clinical effectiveness locally.

Evidence supports rifaximin as effective maintenance therapy to prevent HE recurrence when added to lactulose.

Provincial special‑authority coverage is more commonly available for HE than for IBS‑D across provinces such as Ontario, British Columbia and Quebec.

Ontario Drug Benefit, BC PharmaCare and RAMQ generally list rifaximin under restricted benefits or require special‑authority programs for HE indications.

IBS‑D coverage is uneven and often requires prior therapies to have been tried before approval for public reimbursement.

Common efficacy endpoints used in Canadian registries include hospital readmissions, time to first HE episode and validated IBS symptom scores.

• Common Efficacy Endpoints: Hospital readmissions.
• Common Efficacy Endpoints: Time to first HE episode.
• Common Efficacy Endpoints: IBS symptom scores and bloating scales.

Pharmacists in community chains like Shoppers Drug Mart and Rexall and hospital pharmacists can assist with appeals and documentation when applying for special authority.

• Special Authority: A provincial approval process to reimburse restricted drugs for eligible patients.
• DIN: Drug Identification Number used to identify the specific marketed product.
• Exceptional Drug Status: A program some provinces offer for high‑cost or unusual therapies outside standard formularies.

Clinicians should confirm the product’s DIN and monograph at Health Canada and document clinical rationale when requesting coverage.

Bilingual documentation and Indigenous patient navigation services are critical for equitable access across diverse Canadian communities.

Indications And Expanded Uses

What is rifaximin officially approved for and where is it used off‑label?

Internationally, rifaximin indications include prevention of hepatic encephalopathy, traveller’s diarrhoea and short‑course use for IBS‑D.

In Canada, hepatic encephalopathy prevention has the clearest Health Canada–supported use with provincial funding pathways more frequently available for HE than IBS‑D.

IBS‑D use is common in clinical practice but often off‑label for repeat courses beyond a 14‑day regimen and may lack public coverage.

Emerging Canadian research from small randomised trials and real‑world studies between 2022 and 2024 has explored rifaximin for small intestinal bacterial overgrowth and reducing bacterial translocation in cirrhosis, but evidence remains preliminary.

Clinicians should document symptom severity, previous therapies tried and treatment goals to justify off‑label use to insurers or special‑authority programs.

Many patients in Canadian urban centres express concern about systemic antibiotic exposure and favour non‑systemic agents such as rifaximin or branded alternatives like Zaxine for IBS symptoms.

Composition And Brand Landscape

How is rifaximin formulated and what brands might you encounter in Canada?

Rifaximin is a non‑systemic rifamycin antibiotic designed to act in the gut with minimal systemic absorption.

Globally, Xifaxan is a well known brand and other products such as Zaxine or generic rifaximin tablets are marketed in various countries.

In Canada, brand availability varies by importer and manufacturer, so always verify individual product DINs and monograph text at Health Canada.

The following example from other INN listings shows how INN and national brands are structured in drug listings and why checking the DIN is important.

Example Structuring (Real Data): International Nonproprietary Name (INN) Metformin — Canada: Glumetza, Glucophage.

• Common formulations include 200 mg tablet in some markets and 550 mg tablets for HE/IBS‑D regimens.
• Typical packaging varies by manufacturer and strength and may be different across pharmacies.

Major pharmacy chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs may stock different brands or special‑order rifaximin products.

Generic suppliers and importers can vary the brand available at any time, so pharmacists should verify and counsel accordingly.

Contraindications And Special Precautions

Who should avoid rifaximin and what special precautions matter in Canada?

The absolute contraindication is known hypersensitivity to rifamycins such as rifampin.

Use caution in patients where severe gastrointestinal inflammation or systemic infection is suspected because rifaximin is minimally absorbed and may be insufficient for systemic infection.

Pregnancy and breastfeeding data are limited, so use rifaximin in pregnancy only when the benefits clearly outweigh the risks and in consultation with obstetrical care.

Antibiotic exposure can trigger Clostridioides difficile recurrence, so a history of C. difficile infection is an area for caution and monitoring.

• Hypersensitivity: Known allergy to rifamycins (e.g., rifampin).
• C. difficile Recurrence: Prior episodes increase risk after antibiotic exposure.
• Systemic Absorption: Low, but inadequate for systemic infection.

High‑risk Canadian subpopulations include elderly patients with multiple comorbidities, patients in remote or Indigenous communities with limited follow‑up and patients with recurrent C. difficile.

Health Canada advisories emphasise monitoring for severe diarrhoea and allergic reactions, and pharmacists should document allergies in provincial e‑health records.

In rural or remote settings plan for clear return instructions and follow‑up because delays in access to care can affect safety monitoring.

Dosage Guidelines

What doses are used for each indication and how should patients be counselled?

For hepatic encephalopathy maintenance the typical regimen is rifaximin 550 mg twice daily, usually added to lactulose.

For IBS‑D the common trial regimen is rifaximin 550 mg three times daily for 14 days, with repeat courses considered for recurrence after reassessment.

For traveller’s diarrhoea noninvasive E. coli regimens use rifaximin 200 mg three times daily for three days.

• HE: 550 mg twice daily, ongoing maintenance.
• IBS‑D: 550 mg three times daily for 14 days; reassess for repeat courses.
• Traveller’s Diarrhoea: 200 mg three times daily for 3 days.

Because rifaximin is minimally absorbed, standard dosing is generally used across renal impairment categories, but check the product monograph if severe hepatic impairment coexists.

Pharmacists should verify product strength, match regimen to DIN‑labelled indication and document any off‑label dosing in clinical notes.

Patient counselling should stress adherence, when to stop therapy and when to return for worsening symptoms.

Interactions Overview

Will rifaximin interact with my other medicines?

Rifaximin has few systemic drug interactions because of negligible systemic absorption compared with classic rifamycins like rifampin.

Nevertheless, the Health Canada monograph advises monitoring when patients are taking medications with narrow therapeutic windows such as anticoagulants, immunosuppressants or anticonvulsants.

Warfarin may need INR monitoring during and after an antibiotic course even though rifaximin’s systemic induction potential is limited.

• Warfarin—monitor INR.
• Tacrolimus and cyclosporine—monitor drug levels as a precaution.
• Certain antiepileptics—monitor seizure control and levels where applicable.

“Negligible systemic absorption” means only trace amounts appear in plasma under usual conditions, which reduces but does not eliminate interaction risk.

No major food interactions are documented, but alcohol should be avoided in patients with liver disease or HE as it can worsen hepatic function.

Encourage patients to disclose OTC herbal products such as St. John’s Wort and other supplements that can affect drug metabolism or interact with liver disease management.

Pharmacists should check provincial e‑health medication lists and document counselling at community pharmacies and hospital discharge.

Cultural Perceptions And Patient Habits

How do Canadian patients view rifaximin and what practical concerns come up?

Patients often value rifaximin’s oral, gut‑targeted profile because it reduces concerns about systemic antibiotic exposure.

Antibiotic stewardship considerations are prominent in urban clinical forums and patient groups, and some patients expect clear explanation about resistance risk.

Indigenous and rural communities frequently report access barriers such as distance to a dispensing pharmacy and delays in special‑authority approvals.

• Common Patient Concerns: cost of therapy.
• Common Patient Concerns: duration and need for repeat courses.
• Common Patient Concerns: antibiotic resistance and safety.
• Common Patient Concerns: culturally safe counselling and bilingual materials.

Provincial refill delays are reported in cohort analyses and estimate refill delay percentages are higher in remote areas compared with urban centres.

Community pharmacists bridge many gaps by offering blister packaging, travel counselling and liaising with provincial drug plans for special‑authority applications.

Patient‑facing materials in both English and French and involvement of Indigenous health liaisons improve uptake and understanding in diverse populations.

Availability And Pricing Patterns

Where can patients get rifaximin in Canada and what will it cost them?

Availability depends on importer, DIN listings and pharmacy stocking choices; large chains may special‑order rifaximin or source generics through suppliers.

Rifaximin courses typically cost more than many common oral antibiotics, and public coverage is more likely for hepatic encephalopathy than for IBS‑D.

Some Canadians living near the border consider US sources such as Xifaxan for price differences, but clinicians should caution about formulation differences and legal import rules.

In our online pharmacy, rifaximin is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

• Reimbursement Steps: complete special authority application.
• Reimbursement Steps: provide clinical notes and DIN for product.
• Reimbursement Steps: submit exception codes where applicable.

Pharmacists commonly support patients with prior‑authorization paperwork, PINs for provincial programs and receipts for reimbursement claims.

Comparable Medicines And Preferences

What are the alternatives to rifaximin and how do they compare?

For hepatic encephalopathy, lactulose remains the primary standard and rifaximin is used as an add‑on to reduce readmissions.

For traveller’s diarrhoea alternatives include azithromycin which may be preferred where invasive pathogens are suspected.

For IBS‑D alternatives and adjuncts include loperamide, eluxadoline, a low‑FODMAP diet and neuromodulators depending on symptom profile and comorbidities.

• Pros: Low systemic exposure and targeted gut effect.
• Cons: Higher cost, modest long‑term IBS‑D data and potential C. difficile risk.

Clinicians typically prefer rifaximin for HE maintenance to lower readmission risk, and reserve IBS‑D use for patients who fail first‑line measures.

Clarifying patient goals—symptom relief versus prevention of recurrence—helps select the most appropriate therapy within stewardship and budget constraints.

Faq Section

What do patients ask most about rifaximin?

• Is rifaximin covered by provincial plans? Often covered for hepatic encephalopathy via special authority; IBS‑D coverage varies and documentation such as DIN and monograph may help support applications.
• Can I take rifaximin while pregnant? Data in pregnancy are limited; use only if benefits outweigh risks after discussion with obstetrical care.
• How fast does it work for IBS‑D? Symptom improvement is often seen within days to two weeks; some patients need repeat courses for recurrences.
• Will it cause antibiotic resistance? Local gut resistance may develop; rifaximin’s poor systemic absorption reduces systemic selection pressure, but stewardship remains important.
• What if I live rurally and need refills? Ask your pharmacist to arrange multi‑dose packs, coordinate with telepharmacy services or hospital programs and set up follow‑up remotely.

Clinician Tip: include DIN on paperwork and provide bilingual patient leaflets to support coverage requests and patient understanding.

Guidelines For Proper Use

What should pharmacists and prescribers do at the point of care?

Verify the indication against the Health Canada monograph and record the DIN on prescriptions and supporting documentation.

Complete provincial special‑authority applications where required and include relevant clinical notes such as prior therapy and severity.

At‑dispense counselling should cover dosing, duration, adverse effects and follow‑up instructions.

Counselling Points:

• Take the medication exactly as prescribed and complete the course unless advised otherwise.
• Watch for severe diarrhoea, allergic signs and seek care if symptoms worsen.
• Avoid unnecessary repeat courses without clinical reassessment.
• Provide bilingual instructions and involve Indigenous health liaisons where appropriate.

Pharmacy chains can support adherence with blister packs, SMS reminders and telepharmacy follow‑up, which is especially helpful for remote patients.

Delivery Across Canada (English)